Immunocore Skyrocketed by Europe’s Largest Private Biotech Financing Ever

16/07/2015 - 3 minutes

Immunocore Limited, just announced that it has secured a £205 million financing (€293 m) from private investors to push forward its T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune diseases. This substantial amount of cash not only embodies the largest private investment ever made in Europe by a biotech company, but also the second largest worldwide after Moderna Therapeutics‘s record achievement. 

Immunocore’s technology has everything to seduce investors. The age of monoclonal antibodies has passed, and Biotech companies are now looking for new technologies that combine the power of targeted therapies without resistance induced by monoclonal antibodies. Where other companies decided to develop CAR-T technologies, using boosted T cells, Immunocore went outside the box, and opted for another strategy using T cell receptors.

ImmTAC, Immunocore’s technology, is a new class of bi-specific biologic reagents that combine an affinity-enhanced T cell receptor (TCR)-based targeting system with an anti-CD3 effector function to specifically activate T cell responses to recognise and destroy cancer cells.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following: